Valk Award Memorial Lecture: PET in Precision Medicine: Transiting Molecular Imaging from “Lumpology” to “Biology”
Sponsored by the SNMMI PET Center of Excellence
Twyla B. Bartel, DO, FACNM, FSNMMI; Katherine Zukotynski, BASc, MD, PhD, P.Eng
Katherine Zukotynski, BASc, MD, PhD, P.Eng; Michael V. Knopp, MD, PhD
Rodney Hicks, MD
Peter MacCallum Cancer Institute, Melbourne, Australia
Regulatory authorities, funding agencies, and many clinicians have focused on the ability of PET to find disease sites more accurately than conventional imaging with particular focus on false negative and false positive rates. As our armamentarium of PET tracers increases, there is a need for a frameshift in thinking away from simply detecting to disease (“lumpology” as I like to call this process) towards a deeper understanding of the biology underpinning the uptake of PET tracers. This biology is particularly relevant to the selection and monitoring of targeted therapies and increasingly in assessing the suitability of patients for radionuclide therapy as part of the theranostic paradigm.
1. Explain how FDG moved from being a tracer for the evaluation of glycolytic metabolism to being a “contrast agent” for detecting cancer.
2. Describe how new tracers have supplanted FDG for the detection of some diseases with low FDG-avidity.
3. Discuss why new tracers, and FDG itself, should be reconsidered in the context of modern oncology as agents to phenotype disease within and between patients.
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.